
An early weightlifting study links steroid history and hormone markers with reported aging symptoms. Clinical assessment remains essential.

On July 31, 2026, European Psychiatry published preliminary findings from an ongoing study examining sex hormones and self-reported well-being in midlife male weightlifters. The congress abstract compared men with different anabolic-androgenic steroid (AAS) histories, including former users receiving testosterone replacement therapy (TRT).
This article is for informational purposes only and is not medical advice. Personal questions about symptoms or hormone treatment belong with a qualified clinician.
According to the abstract published in European Psychiatry, participants were midlife male weightlifters with a mean age of about 45. The authors organized the sample by self-reported AAS history:
Keeping the TRT group separate is important for reading the results. Former users receiving treatment were not combined with the other past users. The abstract therefore describes distinct groups rather than treating everyone with any history of AAS use as the same population.
Participants completed questionnaires covering well-being and aging-related symptoms. They also answered questions about masculinity norms and aggression. Blood samples were analyzed for testosterone and free testosterone index (FTI).
The other blood measures were follicle-stimulating hormone and sex hormone-binding globulin (SHBG). The researchers also measured luteinizing hormone and estradiol.
The grouping gives AAS history in male hormonal health a central role in interpreting the comparisons. Current use, past use and past use with TRT were separate categories in the research.
In the preliminary analyses reported by European Psychiatry, past AAS users reported lower quality of life and more aging-related symptoms than the other groups. The abstract gives p-values ranging from less than .01 to .05 for those comparisons.
The authors also found that lower testosterone and FTI were associated with more aging-related symptoms. This result concerns the relationship between measured hormone markers and symptom reporting.
The report therefore contains different kinds of results. One compares participants according to their AAS-history group. Another examines the relationship between blood markers and symptoms. Keeping those findings distinct prevents a group-level observation from being mistaken for a description of every former user.
The central finding is about reported well-being alongside hormone measurements. It is not simply a comparison of testosterone numbers between categories of weightlifters.
The authors reported no association between the hormone markers and aggression. They also found no significant differences in aggression between the participant groups.
This result belongs alongside the symptom findings rather than being folded into them. In this sample, hormone markers were associated with aging-related symptoms but not with aggression. The report did not present the same pattern across every questionnaire outcome.
The AAS groups scored higher than controls on masculinity norms. The abstract reported p < .01 for this comparison.
The authors also reported positive associations between testosterone, FTI and estradiol and several masculinity subscales. The named subscales included “playboy” and power over women. Career pursuit was another.
Those are questionnaire labels from the study. They should be read as reported research measures rather than used to characterize an individual reader or to rank forms of masculinity. They are also separate from the study's aggression findings.
These findings describe associations and group differences. They do not establish that lower testosterone caused symptoms or that AAS use caused poorer well-being. The abstract also cannot establish whether the reported symptoms were clinically attributable to low testosterone.
The relevant outcome was self-reported aging-related symptoms. That is not the same claim as demonstrated acceleration of biological aging. A headline should preserve the distinction rather than turn a symptom score into a statement about how quickly someone's body is aging.
Scope also matters. The participants were male weightlifters in midlife. Results from this sample should not be treated as representative of all men or of people without a weightlifting or AAS history.
The available report is a congress abstract rather than a full-length research article. It does not provide recruitment details or a study location.
Reporting is also too limited to judge the size of the differences. The abstract does not give group means, effect sizes or confidence intervals. Nor does it identify the specific tests behind the symptom and quality-of-life comparisons. The reported p-values do not fill those gaps.
The TRT group should not be read as a treatment experiment. Its inclusion does not establish that TRT improved well-being or that starting treatment would help another former user. The study does not provide a treatment pathway.
Finally, the aggression finding applies to these participants. It does not establish a universal conclusion that testosterone has no relationship with aggression. The authors themselves call for cautious interpretation and further study.
The immediate implication is not a new indication for TRT. It is a reason to keep steroid history and persistent symptoms within a proper clinical assessment.
European Association of Urology guidance sets a different standard from a research correlation. For late-onset hypogonadism, it calls for compatible symptoms alongside biochemical evidence of low morning testosterone on at least two occasions. The guidance recommends morning, fasting testing and repeat measurement before testosterone therapy when results are below its threshold.
This keeps symptoms and laboratory evidence in the same assessment. A symptom questionnaire is not a stand-alone diagnosis. Nor should a single low result be treated as one based on this abstract.
For men concerned about symptoms after past AAS use, the supported practical step is to discuss persistent concerns and relevant history with a qualified clinician. Prior AAS use is part of that discussion. The purpose is an individual assessment rather than an attempt to match oneself to a study group.
Questions consistent with the evidence include:
These are questions for qualified care rather than instructions for self-testing or hormone use. The guideline supplies the clinical framework; the study adds an early observation about a particular sample.
Broader questions about testosterone and aging remain separate from assuming that reported aging symptoms identify a hormone disorder. The useful distinction is between a concern that deserves assessment and a diagnosis that has been established.
The bottom line is that this abstract should not immediately change medical practice. It adds a question for further research while leaving the need for clinical assessment and confirmatory testing intact. Decisions about TRT remain personal medical decisions rather than conclusions that can be drawn from these group comparisons.
Interpreting persistent symptoms after AAS use remains the clinician's task; Testostra makes the hormone evidence easier to follow. Its coverage of male hormonal health addresses uncertainty about possible causes and helps readers form informed questions without treating a research association as a personal diagnosis or a reason to start TRT.
Testostra follows testosterone research, clinical guidance and emerging evidence without turning general information into personal treatment advice.




Send us a question, research idea or topic suggestion. Reader questions help shape future Testostra content.
Contact Testostra